CEFTAZ-250
Description
- Combination of Ceftriaxone 250 mg (cephalosporin) + Tazobactam 31.25 mg (β-lactamase inhibitor)
- Enhanced spectrum of activity, even against resistant bacterial strains
- Effective in treating respiratory, urinary, abdominal, and skin infections
- Suitable for hospital and clinical use via IV or IM injection
- Helps reduce the risk of treatment failure in β-lactamase–producing infections
- Once or twice daily dosing depending on severity and indication
- Safe and well-tolerated when administered under proper medical guidance
Composition
CEFTRIAXONE-250 MG, TAZOBACTUM-31.25 MG
Benefits
CEFTAZ-281.25 offers enhanced antibacterial activity against both Gram-positive and Gram-negative pathogens, including β-lactamase–producing strains that are resistant to standard antibiotics. It is highly effective in treating pneumonia, urinary tract infections, intra-abdominal infections, sepsis, and skin infections. The addition of Tazobactam ensures broader coverage and a reduced risk of treatment failure. CEFTAZ-281.25 delivers reliable, fast-acting results and is well-tolerated in both adult and pediatric patients under medical supervision.
Introduction
CEFTAZ-281.25 is a broad-spectrum injectable antibiotic formulation combining Ceftriaxone 250 mg, a third-generation cephalosporin, with Tazobactam 31.25 mg, a β-lactamase inhibitor. This synergistic combination enhances the effectiveness of Ceftriaxone by inhibiting bacterial resistance mechanisms. CEFTAZ-281.25 is indicated for the treatment of a wide variety of moderate to severe bacterial infections, including those of the respiratory tract, urinary tract, abdominal region, skin, and soft tissues. Its dual mechanism of action provides enhanced efficacy, making it ideal for use in hospital and clinical settings.
